Crossmark

The current state and future directions of RNAi-based therapeutics

Crossref DOI link: https://doi.org/10.1038/s41573-019-0017-4

Published Online: 2019-03-07

Published Print: 2019-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Setten, Ryan L.

Rossi, John J.

Han, Si-ping http://orcid.org/0000-0002-2213-4953
License Information

Text and Data Mining valid from 2019-03-07
More Information

Article History

First Online: 7 March 2019

Change Date: 24 April 2019

Change Type: Correction

Change Date: 18 March 2019

Change Type: Correction

Change Details: Errors in the alignment and structure of the siRNN and in the structure of the sisiRNA in the original version of Fig. 3 have been corrected.

Change Details: The use of the names for patisiran has been made consistent throughout the article in line with the journal style and typographical errors have been corrected.

Competing interests

: J.J.R. is a co-founder of Dicerna Pharmaceuticals and MiNA Therapeutics. S.-p.H. and J.J.R. are inventors on US patents and patent applications for conditional RNA interference-related technologies.